Siemens is improving diagnosis and treatment of diseases with a unique imaging system that locates metabolic processes using nuclear detectors and x-ray images with high accuracy.
Symbia IntevoTM*, the world's first xSPECT* system, integrates metabolic information from single photon emission computed tomography (SPECT) into computed tomography (CT) images.
Previously, SPECT/CT images had low spatial resolution and physicians needed extensive experience and additional follow-up studies to decide whether a metabolic anomaly reflected a tumor or other diseases. Symbia Intevo also enables physicians to determine tumor size and thus plan treatment and monitor outcomes.
During SPECT examinations, patients are given low doses of radiopharmaceuticals that emit radiation when they react with a particular body tissue. Different metabolic processes can thus be observed depending on the agent administered. To determine the location of a metabolic disorder in the body, SPECT information is overlaid with CT images showing the anatomy of the body.
Until now, the problem has been that SPECT examinations offer only low spatial resolution and the high-precision CT images have to be adapted to match them. It can happen that the resulting image no longer clearly shows whether the metabolic disorder observed is inside or outside the bone. It would initially be unclear whether the anomaly was caused by a tumor in the bone or something else, such as a soft tissue inflammation.
The developers at Siemens Healthcare have now integrated SPECT and CT data in such a way that the high spatial resolution of the x-ray images remains intact and the SPECT images are significantly improved. The two datasets are generated sequentially during reconstruction in the same device using reference parameters such as the position of the detectors relative to the patient.
New, iterative image reconstruction algorithms refine the data in several passes. It was not previously possible to perform such complex calculation processes at the high resolution used in the CT images. That's why, in addition to new software, Symbia Intevo is also equipped with a powerful 64-bit computer.
The precise xSPECT data also makes it possible to determine the volume of the radiopharmaceutical used. This means that physicians can observe the change in metabolic activity and check whether their treatment is working.
Symbia Intevo also utilizes state-of-the-art algorithms that use the CT measurements to assign each voxel (three-dimensional pixel) in the xSPECT image to a particular class-fatty tissue, soft tissue, air, or hard (external) and soft (internal) bone areas. This makes it easy to recognize the body part where the metabolic disorder is located.
* Symbia Intevo and xSPECT are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed.
Dr. Norbert Aschenbrenner | Siemens InnovationNews
Imaging identifies asymptomatic people at risk for stroke
16.09.2014 | Radiological Society of North America
Blood-cleansing biospleen device developed for sepsis therapy
15.09.2014 | Wyss Institute for Biologically Inspired Engineering at Harvard
12.09.2014 | Event News
03.09.2014 | Event News
27.08.2014 | Event News
17.09.2014 | Press release
17.09.2014 | Physics and Astronomy
17.09.2014 | Studies and Analyses